ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the best emerging technology stocks to invest in. On December 18, Guggenheim analyst Yatin Suneja raised the firm’s price target on ABIVAX to $175 from$150 with a Buy rating on the shares. This sentiment was posted as the firm cited its optimistic outlook for obefazimod in the 44-week maintenance readout, which is currently upcoming. On December 15, ABIVAX reported its financial results for Q3 2025. The company generated $2.40 million in revenue, surpassing ...